Nuvation Bio (Nuvation Bio) Receivables Turnover : 0.00 (As of Sep. 2021)

View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Nuvation Bio's Revenue for the three months ended in Sep. 2021 was $0.00 Mil. Nuvation Bio's average Accounts Receivable for the three months ended in Sep. 2021 was $0.00 Mil.

Nuvation Bio Receivables Turnover Historical Data

The historical data trend for Nuvation Bio's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Receivables Turnover Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Receivables Turnover

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Receivables Turnover	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Nuvation Bio's Receivables Turnover

For the Biotechnology subindustry, Nuvation Bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Receivables Turnover falls into.

Nuvation Bio Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Nuvation Bio's Receivables Turnover for the fiscal year that ended in Dec. 2020 is calculated as

	Receivables Turnover (A: Dec. 2020 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2020 )	/ (	(Accounts Receivable (A: . 20 )	+	Accounts Receivable (A: Dec. 2020 ))	/	count )
=	0	/ (	(	+	0)	/	1 )
=	0	/	0
=	N/A

Nuvation Bio's Receivables Turnover for the quarter that ended in Sep. 2021 is calculated as

	Receivables Turnover (Q: Sep. 2021 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2021 )	/ (	(Accounts Receivable (Q: Jun. 2021 )	+	Accounts Receivable (Q: Sep. 2021 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Nuvation Bio (NYSE:NUVB.WS) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Nuvation Bio Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.